MX2019001999A - Proceso para la preparacion de microparticulas que contienen acetato de glatiramer. - Google Patents

Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.

Info

Publication number
MX2019001999A
MX2019001999A MX2019001999A MX2019001999A MX2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A MX 2019001999 A MX2019001999 A MX 2019001999A
Authority
MX
Mexico
Prior art keywords
glatiramer acetate
microparticles containing
preparing microparticles
containing glatiramer
preparing
Prior art date
Application number
MX2019001999A
Other languages
English (en)
Inventor
Marom Ehud
Rubnov Shai
Bleich Kimelman Nadav
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of MX2019001999A publication Critical patent/MX2019001999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/36—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino acids, polyamines and polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención proporciona un procedimiento mejorado para la preparación de micropartículas que contienen acetato de glatiramer con bajos niveles de disolventes orgánicos residuales, en particular, diclorometano. Las micropartículas se incorporan en composiciones farmacéuticas parenterales de acción prolongada en forma depot que son adecuadas para administración o inyección subcutánea o intramuscular, y que se pueden utilizar para el tratamiento de la esclerosis múltiple.
MX2019001999A 2016-08-28 2017-08-28 Proceso para la preparacion de microparticulas que contienen acetato de glatiramer. MX2019001999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380426P 2016-08-28 2016-08-28
PCT/IL2017/050954 WO2018042423A1 (en) 2016-08-28 2017-08-28 Process for preparing microparticles containing glatiramer acetate

Publications (1)

Publication Number Publication Date
MX2019001999A true MX2019001999A (es) 2019-08-29

Family

ID=61301634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001999A MX2019001999A (es) 2016-08-28 2017-08-28 Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.

Country Status (10)

Country Link
US (2) US11471421B2 (es)
EP (1) EP3503907B1 (es)
JP (2) JP7232752B2 (es)
CN (1) CN109689082A (es)
AU (1) AU2017319781B2 (es)
BR (1) BR112019003131A2 (es)
CA (1) CA3035149A1 (es)
IL (1) IL264824B (es)
MX (1) MX2019001999A (es)
WO (1) WO2018042423A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230738T1 (hr) * 2016-08-31 2023-10-27 Mapi Pharma Ltd Depo sustavi koji sadrže glatiramer acetat
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
CN111249524B (zh) * 2020-01-18 2020-12-08 南京医科大学附属口腔医院 用于骨组织再生的高孔隙率聚己内酯多孔微球支架及其制备方法
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) 2002-07-15 2003-02-26 裴福兴 一种bFGF－PLGA缓释微球及其制备方法和用途
CA2533649A1 (en) * 2003-07-31 2005-02-03 Yeda Research And Development Co. Ltd. Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
PT3536333T (pt) 2010-01-04 2022-11-11 Mapi Pharma Ltd Sistema de depósito compreendendo acetato de glatirâmero
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
HRP20230738T1 (hr) 2016-08-31 2023-10-27 Mapi Pharma Ltd Depo sustavi koji sadrže glatiramer acetat
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Also Published As

Publication number Publication date
AU2017319781B2 (en) 2021-05-27
CN109689082A (zh) 2019-04-26
EP3503907B1 (en) 2024-03-13
JP7232752B2 (ja) 2023-03-03
IL264824B (en) 2022-03-01
CA3035149A1 (en) 2018-03-08
EP3503907C0 (en) 2024-03-13
WO2018042423A1 (en) 2018-03-08
US20210299057A1 (en) 2021-09-30
AU2017319781A1 (en) 2019-02-07
EP3503907A1 (en) 2019-07-03
BR112019003131A2 (pt) 2019-05-21
US11471421B2 (en) 2022-10-18
JP2023022199A (ja) 2023-02-14
JP2019537551A (ja) 2019-12-26
US20230000782A1 (en) 2023-01-05
EP3503907A4 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
MX2019001999A (es) Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MY194058A (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
MX2017001288A (es) Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano.
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
MX2019006539A (es) Sistemas y metodos para la extraccion de productos naturales.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2020007477A (es) Formulacion para la administracion de arn.
MD20180042A2 (ro) Metode de tratare a stărilor asociate cu activarea complementului dependentă de MASP-2
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
CA2939791C (en) Needle assisted jet injection administration of testosterone compositions
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2017014084A (es) Formulaciones de deposito inyectables.
PH12018550008A1 (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
MX2022006022A (es) Peptido derivado de depdc1 y vacuna que lo contiene.
MX2020004418A (es) Peptido derivado de koc1 y vacuna que lo incluye.
MX369414B (es) Peptido.
PH12019502578A1 (en) Methods of treatment for cervical dystonia
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease